Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12
Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12
DUBLIN, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Tuesday, November 12, 2024, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2024.
2024年11月4日都柏林(GLOBE NEWSWIRE) -- avadel pharmaceuticals公司(Nasdaq: AVDL)是一家專注於改變藥物以改變生活的生物製藥公司，宣佈今天將於2024年11月12日週二上午8:30 Et召開電話會議和直播網絡視頻會議，進行公司更新並討論截至2024年9月30日第三季度的財務業績。
To access the conference call, investors are invited to dial (800) 579-2543 (U.S. and International) and reference the conference ID AVADEL. A live audio webcast of the call be accessed by visiting the investor relations section of the Company's website, . A replay of the webcast will be archived on Avadel's website for 90 days following the event.
要參加電話會議，投資者可撥打(800) 579-2543(美國和國際)，並參考會議ID AVADEL。可通過訪問該公司網站的投資者關係部分來獲取電話會議的現場音頻網絡視頻。網絡視頻會的重播將在活動結束後的90天內存檔在avadel的網站上。
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel's commercial product, LUMRYZ, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years and older with narcolepsy. For more information, please visit .
關於Avadel Pharmaceuticals，plc
avadel pharmaceuticals公司(Nasdaq: AVDL)是一家專注於改變藥物以改變生活的生物製藥公司。我們的方法包括將創新解決方案應用於開發能夠解決患者在當前治療選擇中面臨的挑戰的藥物。avadel的商業產品LUMRYZ獲得美國食品藥品監督管理局(FDA)批准，作爲首個也是唯一一款控制癲癇或白天過度嗜睡(EDS)的奧斯巴特，適用於7歲及以上患有嗜睡病的患者。欲了解更多信息，請訪問。
Investor Contact:
Courtney Mogerley
Precision AQ
Courtney.Mogerley@precisionAQ.com
(212) 698-8687
投資者聯繫人：
Courtney Mogerley
Josh.Rappaport@precisionaq.com
Courtney.Mogerley@precisionAQ.com
(212) 698-8687
Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162
媒體聯繫：
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162
